Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Data published in Molecular PsychiatryAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026-Addex Therapeutics (SIX: ...
Drug Target Review

Targeting mGlu7 could lead to new anxiety and PTSD treatments

Explore innovative anxiety and PTSD treatments with Addex Therapeutics' groundbreaking research on mGlu7 modulators.
Seeking Alpha

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
Healio

Allosteric modulator nonsuperior to placebo in Parkinson’s disease

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
FierceBiotech

Gain hopes to prove Parkinson's drug's potential next year after phase 1 win for allosteric modulator

Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a ...
JSTOR Daily

Activation mechanism of the μ-opioid receptor by an allosteric modulator

Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
Seeking Alpha

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, ...
Monthly Prescribing Reference

Negative Allosteric Modulator Candidate Misses Endpoints in Social Anxiety Disorder Trial

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
Nasdaq

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...